If you are experiencing extreme tiredness, urinal blood, and white areas of your eyes turned yellow, do not think it is jaundice or anaemia. It might be thrombotic thrombocytopenic purpura (TTP). This is a serious condition and requires careful planning. Understand basic treatment options available for TTP that help you make the safest decision for positively treating it at a minimum cost of 25,000 in India.
In acute immune, mediated TTP, therapeutic plasma exchange (TPE) is the primary treatment, with corticosteroids added to TPE to improve outcomes.
Plasma exchange removes abnormal proteins from the liquid portion of blood that contains platelets and blood cells. After that, it replaces the abnormal plasma with healthy donor plasma. Plasma exchange removes ADAMTS13, inhibiting autoantibodies and supplies donor plasma containing functional ADAMTS13, helping restore enzyme activity.
Healthcare providers prescribe medicines to slow down or stop the formation of anti-ADAMTS13 antibodies. Glucocorticoids are typically used to suppress the immune system. Rituximab is conditionally recommended as an adjunct to corticosteroids and TPE during acute episodes and can also help reduce relapse risk.
In certain cases, if plasma exchange and medications do not work, the doctor may recommend a surgical option to remove the spleen. This surgical option is Splenectomy, which treats severe TTP. This treatment is useful when excessive platelets are reportedly destroyed in the spleen.
The overall cost of treating TTP depends on the type of treatment, hospital stay, severity of the patient's condition, and accessibility.
| Type of Treatment | Cost in India (Rs.) |
| Plasma Exchange | 25,000 to 32,000 per session |
| Rituximab | 6,500 to 45,000 per injection |
| Sclenectomy | 1,00,000 to 1,50,000 |
Patients should consult specialists and surgeons to determine the costs of treatment and the number of TTP treatment sessions required based on their medical conditions.
Recovery time depends on the disease severity and the particular treatment option that the patient received. Mostly, TTP patients need a few weeks to recover after plasma therapy. Patients who have undergone splenectomy typically need about four to six weeks for recovery.
TTP treatments typically do not produce any side effects. However, spleen removal may cause high fever or infections in a few patients. At the same time, oral drugs can have adverse effects and increase the risk of ulcer, gastritis, diabetes or hypertension.
Untreated TTP has a mortality rate of about 90%, but with prompt modern treatment, survival exceeds 95%. With proper care, the survival rate can increase to 8 or 9 out of 10 people. This is why an individual must seek medical care after experiencing any symptoms, including altered mental status, headache, yellow skin colouration, breathing issues, blurred vision and fatigue.
Post-treatment guidance of TTP primarily includes the following:
Healthcare providers continue treatment until symptoms improve. Plasma exchange therapy replaces abnormal proteins in the plasma with the normal plasma of a healthy donor to treat acquired TTP. Treatments mostly give a curable solution, but the result may not be permanent since this rare condition can relapse or flare up.